UBS analyst Daniel Brennan maintained a Hold rating on Icon plc (ICLR) today and set a price target of $158.00. The company’s shares closed last Monday at $142.04.
According to TipRanks.com, Brennan is a 3-star analyst with an average return of 2.8% and a 70.7% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Exact Sciences, Fluidigm Corp, and Illumina.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Icon plc with a $166.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $165.14 and a one-year low of $118.10. Currently, Icon plc has an average volume of 228K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ICON plc is a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development.
